Drug Targets and Biomarkers (G285605)

Target Name: DTWD2

NCBI ID: G285605

DTWD2

Drug Targets and Biomarkers

DTWD2: A Potential Drug Target and Biomarker

The development of new drugs and treatments is a constant struggle in the pharmaceutical industry. One of the promising approaches is to target specific proteins, also known as drug targets, to treat various diseases. One of the proteins that has gained significant attention in recent years is DTWD2, which is a potential drug target and biomarker for various diseases, including cancer.

DTWD2: The Protein of the Year

DTWD2, short for doublecortin-related protein 2, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the doublecortin family, which includes several related proteins that play a crucial role in the regulation of various cellular processes in the body.

One of the key functions of DTWD2 is its role in the regulation of pancreatic cancer. Studies have shown that high levels of DTWD2 are associated with poor prognosis in pancreatic cancer patients. Additionally,DTWD2 has also been shown to be overexpressed in various types of cancer, including lung, breast, and ovarian cancer.

Another promising aspect of DTWD2 is its potential as a biomarker for cancer. By measuring the levels of DTWD2 in various types of cancer, researchers may be able to identify early signs of disease and guide treatment decisions. This could be a major step in the development of new cancer treatments.

DTWD2 as a Drug Target

DTWD2 has the potential to be a drug target for various diseases, including cancer. By targeting the protein, researchers may be able to develop new treatments that specifically target DTWD2. This could lead to more effective and less invasive treatments for diseases that are currently difficult to treat.

One of the ways that researchers are exploring DTWD2 as a drug target is through the use of small molecules, also known as inhibitors. These molecules work by binding to the protein and disrupting its function. Researchers have already shown that some small molecules can inhibit the activity of DTWD2 and are currently in the process of testing these compounds for use as treatments.

Another approach that researchers are using is to use antibodies, also known as proteins that recognize specific molecules on the surface of cells. These antibodies can be used to target the protein and block its function. Researchers have already shown that antibodies can effectively inhibit the activity of DTWD2 and are currently in the process of testing these antibodies for use as treatments.

DTWD2 as a Biomarker

DTWD2 has the potential to be a valuable biomarker for cancer. By measuring the levels of DTWD2 in various types of cancer, researchers may be able to identify early signs of disease and guide treatment decisions. This could be a major step in the development of new cancer treatments.

One of the key advantages of using DTWD2 as a biomarker is its stability. Unlike some other biomarkers, such as cancer cells, which can be affected by various factors, including inflammation and cell death, DTWD2 is a stable protein that can be used as a reliable indicator of disease.

Another advantage of DTWD2 is its expression in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. This means that researchers can easily measure the levels of the protein in different types of tissue, which can provide valuable information about the disease.

Conclusion

In conclusion, DTWD2 is a protein that has significant potential as a drug target and biomarker for various diseases, including cancer. Its stability and expression in various tissues make it an attractive candidate for use in new treatments. Further research is needed to fully understand the role of DTWD2

Protein Name: DTW Domain Containing 2

Functions: Catalyzes the formation of 3-(3-amino-3-carboxypropyl)uridine (acp3U) at position 20a in the D-loop of several cytoplasmic tRNAs (acp3U(20a)) (PubMed:31804502). Also has a weak activity to form acp3U at position 20 in the D-loop of tRNAs (acp3U(20)) (PubMed:31804502)

The "DTWD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DTWD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets